Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blinded, Positive-controlled Phase Ⅲ Clinical Trial to Evaluate Lot-to-lot Consistency, Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
Conditions
Interventions
batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)
batch 2 of MCV4
+2 more
Locations
1
Indonesia
Husada Utama Hospital
Surabaya, Indonesia
Start Date
March 20, 2024
Primary Completion Date
July 12, 2024
Completion Date
December 1, 2025
Last Updated
April 3, 2025
NCT02842866
NCT02858570
NCT01339923
NCT02481232
NCT01274897
Lead Sponsor
CanSino Biologics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions